Palmar Psoriasis Treatment: A Complete Guide to Relief and Recovery

Palmar psoriasis is a painful and often debilitating condition. It is also known as hand psoriasis.

It affects the palms of the hands, making daily tasks like typing, cooking, or shaking hands genuinely difficult.

The thick skin of the palm makes treatment more challenging than psoriasis on other parts of the body.

Yet, with the right approach, significant relief is absolutely possible.

This guide covers everything you need to know about palmar psoriasis treatment — from topical creams to advanced biologics — all backed by the latest clinical evidence.

What Is Palmar Psoriasis?

Palmar psoriasis is a subtype of palmoplantar psoriasis (PPP).

It specifically targets the palms of the hands with red, scaly, thickened, or cracked skin.

In some cases, small sterile pustules may appear — a form known as palmoplantar pustulosis.

The condition is chronic. It follows cycles of flares and remissions.

Despite affecting a small body surface area, it causes disproportionate functional and emotional distress.

How Common Is It?

Palmoplantar psoriasis affects around 3–4% of all psoriasis patients.

Because less than 10% of body surface area is usually involved, patients are often excluded from large clinical trials, which has historically limited treatment research.

Thankfully, this gap is now being addressed with newer targeted therapies.

Recognising the Symptoms of Palmar Psoriasis

Key symptoms include:

• Thickened, scaly skin: Silvery-white scales on a red base, typical of plaque psoriasis.
• Deep cracks and fissures: Painful splits in the skin that can bleed.
• Burning and itching: Persistent discomfort that worsens with friction.
• Pustules: Yellow-white blisters that dry and peel — more common in palmoplantar pustulosis.
• Nail changes: Pitting or discolouration, appearing in some patients.

Symptoms can significantly limit daily function and reduce quality of life.

Causes and Triggers of Palmar Psoriasis

Palmar psoriasis is an immune-mediated condition.

The immune system mistakenly accelerates skin cell growth, causing a build-up of plaques.

Genetics plays a key role. The HLA-Cw6 gene is the most common genetic factor associated with the condition.

Common Triggers to Avoid

• Physical friction: Repetitive hand use, manual labour, or tight gloves.

• Stress: Psychological stress is a well-known flare trigger.

• Smoking: Strongly associated with palmoplantar pustulosis; quitting can improve outcomes.

• Certain medications: Beta-blockers, lithium, and NSAIDs may worsen psoriasis.

• Infections: Bacterial or viral infections can trigger flares.

• Harsh soaps and chemicals: Irritate the already-compromised skin barrier.

How Is Palmar Psoriasis Diagnosed?

Diagnosis is primarily clinical — based on the appearance and location of lesions.

A dermatologist will assess the severity using the Palmoplantar Psoriasis Area and Severity Index (PPASI).

This tool measures erythema (redness), induration (thickness), and desquamation (scaling) on a scale of 0–4.

In unclear cases, a skin biopsy may be performed to rule out eczema or fungal infections.

Blood tests can identify associated conditions like psoriatic arthritis or metabolic syndrome.

Palmar Psoriasis Treatment: A Step-by-Step Approach

Treatment follows a stepwise approach — from topical therapies to systemic drugs to biologics.

The goal is to clear lesions, prevent flares, and improve quality of life.

Step 1: Topical Treatments (First-Line Therapy)

Topical therapies are the starting point for most patients with mild to moderate palmar psoriasis.

Potent Topical Corticosteroids

These are the most commonly prescribed first-line treatments.

Agents like clobetasol propionate are applied twice daily, with or without occlusion.

Occlusion — wrapping the hands in plastic or cotton gloves after application — enhances penetration through the thick palmar skin.

The frequency is gradually reduced over weeks to months to minimise side effects.

Vitamin D Analogues (Calcipotriene/Calcipotriol)

Calcipotriene is often combined or alternated with topical corticosteroids.

It slows skin cell growth and reduces inflammation.

Important note: calcipotriene should never be combined with salicylic acid, which deactivates the molecule.

Salicylic Acid

Salicylic acid-based ointments help soften and remove thick, hyperkeratotic plaques.

This improves the penetration of other topical treatments.

It is particularly useful before applying corticosteroids or phototherapy.

Coal Tar Preparations

Coal tar has a long history of use in psoriasis management.

A randomised study found coal tar combination therapy (with clobetasol and salicylic acid) was more effective than solar PUVA irradiation for plantar lesions.

It is less popular today due to its smell and staining properties but remains a cost-effective option.

Tazarotene Ointment

Tazarotene, a topical retinoid, can be effective in reducing scaling and thickness.

It works by normalising skin cell turnover.

It is usually combined with a corticosteroid to reduce irritation.

Step 2: Phototherapy (Second-Line Treatment)

When topical treatments alone are insufficient, phototherapy is the next step.

PUVA Therapy (Psoralen + UVA)

PUVA involves applying a photosensitising agent (psoralen) before UVA light exposure.

Local PUVA — applied only to the hands — is particularly effective and minimises whole-body radiation.

Studies show PUVA is especially effective for palmar lesions.

Narrowband UVB (NB-UVB)

NB-UVB is a safer alternative to PUVA with fewer long-term side effects.

It is often used when PUVA is not tolerated or contraindicated.

308-nm Excimer Laser

The excimer laser delivers targeted UV light precisely to affected areas.

This minimises exposure of healthy skin while maximising treatment effect.

It is particularly useful for localised, resistant lesions.

Step 3: Systemic Treatments

Systemic medications are used for moderate to severe palmar psoriasis that has not responded to topical or light therapies.

Acitretin (Retinoid)

Acitretin is the most widely used oral retinoid for palmoplantar psoriasis without joint involvement.

The dose ranges from 10 mg to 50 mg per day.

Maximum benefit is typically seen between three and six months of treatment.

It is contraindicated in pregnancy and requires regular liver function monitoring.

Methotrexate

Methotrexate is a well-established systemic agent for moderate-to-severe psoriasis.

It is dosed at 7.5 mg to 20 mg per week over three to six weeks.

Known side effects include hepatitis and gastrointestinal discomfort.

Regular blood monitoring is essential during treatment.

Cyclosporine

Cyclosporine works quickly and is used for severe, recalcitrant cases.

It is suitable for immunocompetent patients but limited to short-term use due to nephrotoxicity and hypertension risks.

Apremilast (PDE4 Inhibitor)

Apremilast is an oral, targeted small molecule that inhibits the enzyme phosphodiesterase-4 (PDE4).

A randomised phase 2 trial involving 90 patients showed apremilast 30 mg twice daily significantly outperformed placebo at week 16.

It offers a favourable safety profile without the need for blood monitoring — a significant practical advantage.

Step 4: Biologic Therapies (Advanced Treatment)

Biologics represent the most advanced treatment option for severe, treatment-resistant palmar psoriasis.

They target specific immune pathways involved in psoriasis inflammation.

IL-17 Inhibitors

IL-17A plays a key role in palmoplantar psoriasis pathogenesis.

Secukinumab (an anti-IL-17A antibody) has emerged as one of the most effective biologic options.

A network meta-analysis identified secukinumab 300 mg as the most effective treatment for palmoplantar psoriasis among anti-IL-17A agents.

Ixekizumab (local micro-dose injection) is also being investigated as a promising option.

IL-23 Inhibitors

Guselkumab and risankizumab are approved for palmoplantar pustulosis in Japan and South Korea.

In a compelling case report, a patient with a 15-year history of resistant palmar psoriasis achieved complete lesion resolution after just four doses of risankizumab.

Real-world data from European settings also shows that 56.3% of patients achieved PPPASI-50 at 12 weeks with IL-23 inhibitors.

Bimekizumab

Bimekizumab, which targets both IL-17A and IL-17F, has shown efficacy in severe palmoplantar pustular psoriasis in recent 2024 studies.

It has been approved for psoriatic arthritis since 2024, with potential expanding indications.

Ayurvedic and Holistic Approaches to Palmar Psoriasis

Many patients seek natural or complementary treatments alongside conventional medicine.

Ayurveda views psoriasis as a ‘Kushtha’ — a disease rooted in Vata-Kapha imbalance. Learn more about Ayurvedic psoriasis treatment and how it can complement modern dermatological care.

Evidence-Based Natural Options

Turmeric (Curcumin): Anti-inflammatory properties may reduce redness and scaling. Some studies support its use as an adjunct therapy.

Aloe Vera: Topical aloe vera gel can soothe irritation and moisturise cracked palmar skin.

Fish Oil (Omega-3): May reduce systemic inflammation; generally well-tolerated.

Dead Sea Salt Baths: Mineral-rich soaks can soften plaques and reduce itching.

Neem: Used in Ayurvedic formulations for its antibacterial and anti-inflammatory properties.

Always consult your dermatologist before adding any alternative therapy to your treatment plan.

Lifestyle Modifications for Better Outcomes

Treatment alone is not enough. Lifestyle changes can meaningfully reduce flare frequency.

Moisturise consistently: Apply thick emollients (like petroleum jelly or urea-based creams) multiple times daily. This is non-negotiable for palmar psoriasis.

Wear protective gloves: Use cotton-lined gloves for household chores. Avoid latex gloves, which can irritate.

Quit smoking: Smoking is strongly linked to palmoplantar pustulosis. Quitting has been shown to reduce severity.

Reduce stress: Mindfulness, yoga, and regular sleep can lower cortisol levels and reduce flare frequency.

Avoid harsh soaps: Switch to fragrance-free, pH-balanced cleansers.

Maintain a healthy weight: Obesity is associated with more severe psoriasis and poorer treatment response.

Monitoring Treatment Progress

Tracking your response to treatment is essential.

Dermatologists use two validated tools:

• PPASI (Palmoplantar Psoriasis Area and Severity Index): Measures erythema, induration, and desquamation.

• PPPASI (Palmoplantar Pustulosis Psoriasis Area and Severity Index): Used specifically for pustular forms.

Photography of the palms at regular intervals is a simple and practical way to document progress.

Review appointments every 4–12 weeks are standard, depending on the treatment modality.

Seeking Expert Treatment in Bangalore

If you are based in India, access to expert dermatological care is essential. Specialised psoriasis treatment in Bangalore is available at several leading dermatology and integrative medicine centres.

Bangalore-based dermatologists experienced in palmoplantar psoriasis can offer the full spectrum — from topical regimens to advanced biologics and phototherapy.

Early specialist intervention helps prevent the condition from becoming recalcitrant and reduces long-term impact on quality of life.

Real Patient Outcomes

Clinical outcomes can vary significantly between individuals. Reviewing psoriasis case studies can help patients and caregivers understand realistic expectations and the range of treatment journeys.

For example, a 15-year case of resistant palmoplantar psoriasis achieved complete remission after ayurvedic psoriasis treatment — highlighting how newer treatments can succeed where conventional therapy has failed.

When to See a Dermatologist

Do not delay in seeking professional advice if:

• Your palmar psoriasis is not responding to over-the-counter treatments after 4–6 weeks.
• You have painful cracks that interfere with daily activities.
• Pustules are spreading or worsening rapidly.
• You develop joint pain — this may indicate psoriatic arthritis, which requires separate management.
• Your condition is causing significant emotional distress.

A dermatologist can create a personalised treatment plan tailored to your severity, lifestyle, and medical history.

Limitations of Palmar Psoriasis Treatment

Palmar psoriasis is one of the most treatment-resistant forms of psoriasis.

Understanding these limitations helps patients set realistic expectations.

Why Palmar Psoriasis Is Harder to Treat

Thick stratum corneum: The palmar skin is significantly thicker than elsewhere on the body. This reduces topical drug penetration and makes surface treatments less effective.

Constant friction and pressure: Hands are in near-constant use. This disrupts the skin barrier, reactivates inflammation, and slows healing.

No standardised protocol: Unlike plaque psoriasis, there is no universally agreed treatment guideline for palmoplantar psoriasis. Most treatment decisions are based on limited clinical evidence.

Exclusion from clinical trials: Because less than 10% of body surface area is typically affected, palmoplantar patients have historically been excluded from large psoriasis trials — leaving significant evidence gaps.

High recurrence rates: Even with successful treatment, relapses are common. Many patients need long-term maintenance therapy.

Treatment resistance: A significant proportion of patients do not achieve adequate clearance even after multiple treatment lines. Switching therapies is often necessary.

Limitations of Specific Treatment Approaches

Topical steroids: Long-term use can cause skin thinning (atrophy), stretch marks, and rebound flares on discontinuation. Effectiveness reduces with prolonged use (tachyphylaxis).

Phototherapy: Requires multiple clinic visits per week, making it impractical for many patients. Long-term PUVA use increases the risk of skin ageing and skin cancer.

Systemic agents: Limited by cumulative toxicity. Methotrexate requires liver monitoring; cyclosporine is restricted to short-term use due to kidney and blood pressure risks.

Biologics: Expensive and not always accessible. Require injections and regular monitoring. Some patients develop loss of response over time. Long-term safety data, particularly for newer agents, is still accumulating.

Apremilast: Lower efficacy compared to biologics. Common side effects include nausea and diarrhoea in the early weeks of treatment.

Side Effects of Palmar Psoriasis Medications

Every treatment carries potential side effects. Knowing them helps patients and clinicians weigh the risks against the benefits.

Topical Corticosteroids

• Skin atrophy: Thinning of the skin with prolonged use, particularly under occlusion.

• Telangiectasia: Visible small blood vessels on the skin surface.

• Rebound flare: Sudden worsening of psoriasis when corticosteroids are stopped abruptly.

• Contact dermatitis: Allergic or irritant reaction in some patients.

• Systemic absorption: Rare with proper use, but high-potency steroids under occlusion can suppress the adrenal glands.

Acitretin (Oral Retinoid)

• Teratogenicity: Strictly contraindicated in pregnancy. Women must avoid pregnancy during treatment and for 3 years after stopping.

• Dry skin and lips: Very common; use of emollients and lip balms is essential.

• Elevated triglycerides and cholesterol: Regular lipid monitoring is required.

• Liver toxicity: Liver function tests must be monitored throughout treatment.

• Hair thinning: Can occur, particularly at higher doses.

• Photosensitivity: Increased sensitivity to sunlight; sun protection is important.

Methotrexate

• Hepatotoxicity: Liver fibrosis and cirrhosis with long-term use. Regular liver function tests and occasional biopsy may be needed.

• Bone marrow suppression: Can reduce blood cell counts; full blood count monitoring is mandatory.

• Nausea and mouth ulcers: Common, particularly in early treatment. Folic acid supplementation helps reduce these effects.

• Teratogenicity: Must be avoided in pregnancy. Effective contraception is essential.

• Pulmonary toxicity: Rare but serious; any new breathlessness should be reported immediately.

Cyclosporine

• Nephrotoxicity: Kidney damage is the most significant risk; creatinine levels must be monitored regularly.

• Hypertension: Blood pressure should be checked at every visit.

• Increased infection risk: Immune suppression makes patients vulnerable to infections.

• Gingival overgrowth and hypertrichosis: Excess gum tissue and body hair growth are cosmetic but common side effects.

• Drug interactions: Interacts with many common medications; a thorough medication review is essential before starting.

Apremilast

• Gastrointestinal symptoms: Nausea, diarrhoea, and stomach cramps are most common in the first 2–4 weeks and usually settle.

• Headache: Reported in early treatment.

• Weight loss: Unexplained weight loss has been noted; monitoring is advisable.

• Depression: Rare but reported; patients with a history of depression should be monitored closely.

Biologics (IL-17 and IL-23 Inhibitors)

• Increased infection risk: Upper respiratory tract infections and candida (fungal) infections are more common, particularly with IL-17 inhibitors.

• Injection site reactions: Redness, swelling, or discomfort at the injection site.

• Inflammatory bowel disease: IL-17 inhibitors should be used with caution in patients with Crohn’s disease, as they may worsen the condition.

• Reactivation of latent infections: Tuberculosis (TB) screening is mandatory before starting biologic therapy.

• Malignancy risk: Long-term immunosuppression carries a theoretical risk; regular skin cancer screening is recommended.

• Loss of response: Some patients develop anti-drug antibodies over time, reducing effectiveness.

All biologic therapies require pre-treatment screening and ongoing monitoring throughout the treatment course.

Phototherapy (PUVA)

• Skin ageing (photoageing): Long-term PUVA accelerates skin ageing.

• Increased skin cancer risk: Particularly squamous cell carcinoma with cumulative high-dose PUVA.

• Nausea: Associated with oral psoralen intake; taking it with food helps.

• Eye damage: UV-protective goggles must be worn during and after treatment sessions to protect against cataracts.

Conclusion

Palmar psoriasis is a challenging but treatable condition.

Starting with potent topical corticosteroids and advancing to phototherapy, systemic agents, or biologics when needed provides a clear pathway to better skin.

The emergence of IL-17 and IL-23 inhibitors has transformed outcomes for patients with severe or resistant disease.

Combined with lifestyle changes, regular monitoring, and expert medical care, most patients can achieve meaningful and lasting relief.

If you or a loved one is struggling with palmar psoriasis, speak with a qualified dermatologist today.

Frequently Asked Questions (FAQs)

References

1. NCBI StatPearls – Palmoplantar Psoriasis. Available at: https://www.ncbi.nlm.nih.gov/books/NBK448142/
2. OAText – Palmoplantar Psoriasis: A Review of Topical Therapies. Available at: https://www.oatext.com/Palmoplantar-Psoriasis-a-review-of-topical-therapies.php
3. PubMed – An Update on Therapeutic Options for Palmoplantar Pustulosis. PMID: 36970858. Available at: https://pubmed.ncbi.nlm.nih.gov/36970858/
4. ScienceDirect – Efficacy of Anti-IL-17A Biological Agents for Palmoplantar Psoriasis: A Network Meta-Analysis. Journal of Allergy and Clinical Immunology, 2024.
5. MDPI Journal of Clinical Medicine – Emerging Therapies for PPP with a Focus on IL-23 Inhibitors. Published May 2025. Available at: https://www.mdpi.com/2077-0383/14/10/3273
6. PMC – Palmoplantar Psoriasis Successfully Treated With Risankizumab. Cureus. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8462392/
7. Medscape – Pustular Psoriasis Treatment & Management. Available at: https://emedicine.medscape.com/article/1108220-treatment
8. JCAD – From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments. Available at: https://jcadonline.com/2024-updates-in-psoriasis-treatments/
9. International Psoriasis Council – Palmoplantar Pustulosis: Why Current Treatments Still Fall Short. Available at: https://psoriasiscouncil.org/expert-insights/palmoplantar-pustulosis/
10. Tandfonline – A Systematic Review of Recent RCTs for Palmoplantar Pustulosis. Available at: https://www.tandfonline.com/doi/full/10.1080/09546634.2024.2414048ent plan.
11. Miceli A, Schmieder GJ. Palmoplantar Psoriasis. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448142/
12. https://dermnetnz.org/topics/psoriasis-of-the-palms-and-soles
13. https://www.medicalnewstoday.com/articles/314742